All News

Intimacy after a cancer diagnosis can be difficult due to emotional and physical side effects, but it can also be an important part of healing.

Information and advice about bone marrow transplants from the man who owns one

I went into dating after cancer with one goal, a decent date, and I got far more than I ever dreamed.

The FDA has granted approval to Lenvima (lenvatinib) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase 3 SELECT trial.

It's isolating to have cancer. Making a connection with someone who understands makes all the difference.

Richard Finn, of the Jonsson Comprehensive Cancer Center at UCLA and lead investigator of the PALOMA-1 study, explains the clinical implications of Ibrance's approval for hormone-positive, HER2-negative metastatic breast cancer.

With a deadline of April 14, the FDA will soon make its final approval decision on lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).

Immunotherapies have strong potential as a treatment option for patients with NSCLC, as clinical trials have shown dramatic and durable results.

Ixazomib, also known as MLN9708, met its primary endpoint of improving progression-free survival at an interim analysis of a phase 3 trial of relapsed or refractory multiple myeloma.

At least 10 vaccine candidates have entered advanced testing phases on the strength of impressive early stage results.

Medicare will immediately cover lung cancer screening with low-dose computed tomography (LDCT) for high-risk individuals, including current and former smokers, according to a national coverage determination (NCD) released by CMS.

We have all heard that personalized medicine holds great promise for cancer treatment, but what does it really mean?

My goal is to educate doctors around the globe about helping to diagnose Lynch syndrome and to continue to help patients who need support.

Thanks to The Cancer Genome Atlas (TCGA) Research Network, researchers now have a better understanding of genomic alternations in head and neck cancers.

Issues of fertility, body image and sexuality are all important when treating a young adult with cancer, yet many facilities lack proper utilities and training to assist this group of patients, which is why Anne Katz wrote the book, "This Should Not Be Happening: Young Adults with Cancer."

On the evolving role of PARP inhibitors in the treatment of ovarian cancer, Donna McNamara, co-chief of Gynecological Oncology at the John Theurer Cancer Center (JTCC), discusses the impact of these studies and the outlook going forward.

There's a list of things we're supposed to do as good patients. And then, there's the reality of living with cancer and doing the best we can.

Women diagnosed with early-stage breast cancer have a variety of decisions to make regarding treatment, but it's important for patients to realize all of their options when making those medical decisions.

In which Kevin introduces himself, catches the world up to date on his cancer battle, and sprinkles in some random bits of wisdom

A phase 3 study of Gazyva in indolent non-Hodgkin lymphoma has been stopped early after an interim analysis found the drug improved progression-free survival.

Each year on Feb. 4, people from around the world recognize World Cancer Day, an initiative to increase awareness of the global burden of cancer and promote strategies for reducing cancer incidence and death rates.

The anticipated approval of Ibrance (palbociclib) came two months ahead of expectations, as the FDA granted an accelerated approval to the drug as a frontline treatment for women with ER-positive, HER2-negative metastatic breast cancer.

Carl Harrington, president of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), explains the importance of Imbruvica's approval for the rare disease.

The Food and Drug Administration (FDA) granted a priority review to Yondelis to treat patients with the disease, including liposarcoma and leiomyosarcoma subtypes, who have previously received chemotherapy that included an anthracycline. The FDA will make its final approval decision within six months.

Knowing how genes and nutrients interact could likewise be the prescription for improved health.

Cancer moves fast; we need to move faster. Help make sure patients have access to important diagnostic tests.

The PD-L1 inhibitor MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer (NSCLC) that has progressed on prior therapy.

The FDA's framework for regulating lab developed tests could keep some patients from receiving validated diagnostic tests and targeted treatments like mine.